Skip to main content

Table 1 Effect of 3,6-dihydroxyflavone on cancer endpoints and body weight

From: MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis

Group Total number of rats Number of rats with tumor Incidence (%) Multiplicity (average number/rat) Latency (days) Final body weight (g)
No treatment 8 0 0 - - 291.3 ± 5.2
MNU only 14 13 92.8 2.6 ± 0.6 74.4 ± 7.1 281.7 ± 4.8
MNU + 10 mg/kg 3,6-DHF 14 9 64.3 2.2 ± 0.3 80.8 ± 7.8 275.5 ± 5.8
MNU + 20 mg/kg 3,6-DHF 14 8* 57.1* 1.9 ± 0.4* 87.5 ± 5.1** 278.7 ± 5.1
  1. Data presented as mean ± standard deviation. *P < 0.05, **P < 0.01 compared with the 1-methyl-1-nitrosourea (MNU)-only treatment group. Tumor incidence in the MNU + 20 mg/kg 3,6-dihydroxyflavone (3,6-DHF) treatment group was significantly lower than that in the MNU-only treatment group, indicating that oral administration of 3,6-DHF (20 mg/kg/day) can effectively suppress MUN-induced mammal carcinogenesis.